

10/089,819

-2-

PC17885 (A0000005/1)

**Amendments to the Claims:****RECEIVED  
CENTRAL FAX CENTER  
AUG 01 2006**

1. (Currently Amended) A method for treating diabetic neuropathy comprising administering to a patient in need of treatment an effective amount of a synergistic combination of a NK<sub>1</sub> receptor antagonist selected from [2-(1*H*-indol-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethylester [R-(R\*,S\*)] and (2-methoxy-benzyl)-((2*S*,3*S*)-2-phenyl-piperidin-3-yl)-amine, and a GABA analog selected from gabapentin and pregabalin.
2. (Original) A method of Claim 1 wherein the ratio of the GABA analog relative to the NK<sub>1</sub> receptor antagonist is from 50:1 to 1:1 expressed as parts by weight.
3. (Original) A method according to Claim 1 wherein the ratio of the GABA analog relative to the NK<sub>1</sub> receptor antagonist is 20:1 expressed as parts by weight.
4. (Original) A method according to Claim 1 wherein the NK<sub>1</sub> receptor antagonist is [2-(1*H*-indol-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethylester [R-(R\*,S\*)].
5. (Original) A method according to Claim 1 wherein the GABA analog is gabapentin.
6. (Original) A method according to Claim 1 wherein the GABA analog is pregabalin.
7. (Previously presented) A method according to Claim 1 employing [2-(1*H*-indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester[R-(R\*,S\*)] and gabapentin.
8. (Previously Presented) A method according to Claim 1 employing [2-(1*H*-indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester[R-(R\*,S\*)] and pregabalin.
9. (Canceled)
10. (Canceled)

10/089,819

-3-

PC17885 (A0000005/1)

11. (Canceled)
12. (Canceled)
13. (Canceled)
14. (Canceled)
15. (Canceled)
16. (Canceled)
17. (Canceled)
18. (Canceled)
19. (Previously Presented) A method according to Claim 1 wherein the NK<sub>1</sub> receptor antagonist is (2-methoxy-benzyl)-((2S,3S)-2-phenyl-piperidin-3-yl)-amine.
20. (Previously Presented) A method according to Claim 1 employing (2-methoxy-benzyl)-((2S,3S)-2-phenyl-piperidin-3-yl)-amine and gabapentin.
21. (Previously Presented) A method according to Claim 1 employing (2-(1*H*-indol-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl)-carbamic acid benzofuran-2-ylmethylester [R-(R\*,S\*)] and pregabalin.
22. (Canceled)
23. (Canceled)